Robert Bruce's CRBU Position Overview
Robert Bruce (via Bruce & Co., Inc.) currently holds 250,000 shares of Caribou Biosciences, Inc. (CRBU) worth $440,000, representing 0.12% of the portfolio. First purchased in 2023-Q1, this medium-term investment has been held for 14 quarters.
Based on 13F filings, Robert Bruce has maintained a strategic position in CRBU, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2023, adding 100,000 shares. Largest reduction occurred in Q4 2024, reducing 50,000 shares.
Analysis based on 13F filings available since 2013 Q2
Robert Bruce's Caribou Biosciences (CRBU) Holding Value Over Time
Track share changes against reported price movement
Quarterly Caribou Biosciences (CRBU) Trades by Robert Bruce
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2024 | -50,000 | Reduce 16.67% | 250,000 | $1.59 |
| Q2 2024 | +100,000 | Add 50.00% | 300,000 | $1.64 |
| Q2 2023 | +100,000 | Add 100.00% | 200,000 | $4.25 |
| Q1 2023 | +100,000 | New Buy | 100,000 | $5.31 |
Robert Bruce's Caribou Biosciences Investment FAQs
Robert Bruce first purchased Caribou Biosciences, Inc. (CRBU) in Q1 2023, acquiring 100,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Robert Bruce has held Caribou Biosciences, Inc. (CRBU) for 14 quarters since Q1 2023.
Robert Bruce's largest addition to Caribou Biosciences, Inc. (CRBU) was in Q1 2023, adding 100,000 shares worth $531,000.
According to the latest 13F filing for Q2 2026, Robert Bruce's firm, Bruce & Co., Inc., owns 250,000 shares of Caribou Biosciences, Inc. (CRBU), valued at approximately $440,000.
As of the Q2 2026 filing, Caribou Biosciences, Inc. (CRBU) represents approximately 0.12% of Robert Bruce's publicly disclosed stock portfolio, making it one of their key holdings.
Robert Bruce's peak holding in Caribou Biosciences, Inc. (CRBU) was 300,000 shares, as reported at the end of Q2 2024.